(EPS with Complex Capital Structure) Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgerald’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017.
FITZGERALD PHARMACEUTICAL INDUSTRIES
SELECTED BALANCE SHEET
INFORMATION
JUNE 30, 2017
Long-term debt
Notes payable, 10% \( 1,000,000
8% convertible bonds payable 5,000,000
10% bonds payable 6,000,000
Total long-term debt \)12,000,000
Shareholders’ equity
Preferred stock, 6% cumulative, \(50 par value,
100,000 shares authorized, 25,000 shares issued
and outstanding \) 1,250,000
Common stock, \(1 par, 10,000,000 shares authorized,
1,000,000 shares issued and outstanding 1,000,000
Additional paid-in capital 4,000,000
Retained earnings 6,000,000
Total shareholders’ equity \)12,250,000
The following transactions have also occurred at Fitzgerald.
1. Options were granted on July 1, 2016, to purchase 200,000 shares at \(15 per share. Although no options were exercised
during fiscal year 2017, the average price per common share during fiscal year 2017 was \)20 per share.
2. Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per \(1,000
bond. The bonds are exercisable after 5 years and were issued in fiscal year 2016.
3. The preferred stock was issued in 2016.
4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2017.
5. The 1,000,000 shares of common stock were outstanding for the entire 2017 fiscal year.
6. Net income for fiscal year 2017 was \)1,500,000, and the average income tax rate is 40%.
Instructions
For the fiscal year ended June 30, 2017, calculate the following for Fitzgerald Pharmaceutical Industries.
(a) Basic earnings per share.
(b) Diluted earnings per share.
